Stay informed with the latest headlines
JPMorgan on Thursday shared updated thoughts on Ultragenyx Pharmaceutical Inc’s (NASDAQ:RARE) setrusumab program in osteogenesis imperfecta (OI).In a fourth-quarter 2024 press release, the company said patients continue dosing in the Phase 3 Orbit and Cosmic trials, which evaluate setrusumab in pediatric and young adult patients with OI.The randomized, placebo-controlled Phase 3 portion of the Orbit […]
Read More
Intuitive Surgical, Inc. (NASDAQ:ISRG) is announcing its fourth-quarter earnings on Thursday. Wall Street expects $1.79 in EPS and $2.25 billion in revenues as the company reports after market hours.The stock is up 63.75% over the past year, 16.06% YTD. Intuitive Surgical enters earnings season at record highs, with shares recently hitting an all-time high of […]
Read More
On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, […]
Read More